BioCentury | Sep 16, 2015
Company News

Management tracks

...Inc. (Cambridge, Mass.) hired Kim Drapkin as CFO. She was a financial consultant. Ophthalmology company Makindus Inc....
BioCentury | Jun 16, 2014
Clinical News

MI-100 regulatory update

...Stargardt's disease. The company will begin Phase III testing for the product early next year. Makindus...
...reference data on safety and efficacy from the scientific literature or from previously approved products. Makindus...
...FDA approval for Stargardt's, plus single-digit royalties. Makindus declined to disclose a description of MI-100. Makindus Inc....
Items per page:
1 - 2 of 2
BioCentury | Sep 16, 2015
Company News

Management tracks

...Inc. (Cambridge, Mass.) hired Kim Drapkin as CFO. She was a financial consultant. Ophthalmology company Makindus Inc....
BioCentury | Jun 16, 2014
Clinical News

MI-100 regulatory update

...Stargardt's disease. The company will begin Phase III testing for the product early next year. Makindus...
...reference data on safety and efficacy from the scientific literature or from previously approved products. Makindus...
...FDA approval for Stargardt's, plus single-digit royalties. Makindus declined to disclose a description of MI-100. Makindus Inc....
Items per page:
1 - 2 of 2